ReviewDysglycemia associated with quinolones
Introduction
Antimicrobial therapy is widely used as part of treatment of outpatient or inpatient infectious diseases. Whether through parenteral or enteral routes, antibiotics are well known to have a wide range of adverse events, namely blood glucose disturbances. In addition, severe infections can predispose patients to both hypoglycemia and hyperglycemia. Dysglycemic events were found to occur with several classes of antibiotic use and are not restricted to diabetic patients.
Section snippets
Methods
We searched Medline for literature published on fluoroquinolone-associated dysglycemia with no time limit starting 1946 until present. We used the following MESh to search separately for hyperglycemia and anti-bacterial agents, and hypoglycemia and anti-bacterial agents. The first search lead to 189 articles and the second to 207 articles. Screening and selection of the relevant articles narrowed the search to a total of 91 articles.
The fluoroquinolone antibiotics are widely used because they
Conclusion
Dysglycemia have been documented to occur in a wide range of antimicrobials. Most of which occurred with the use of quinolones. Several factors play an important role in the prediction of the occurrence and the degree of hypoglycemia or hyperglycemia. Therefore, it may be prudent to use them with caution in patients who are prone to hypoglycemia and hyperglycemic events, such as individuals with diabetes
Conflict of interest
The authors state that they have no conflict of interest.
References (22)
- et al.
Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature
Clin. Ther.
(2006) - et al.
Hypoglycemia associated with the use of gatifloxacin
Am. J. Med. Sci.
(2005) Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients
J. Am. Board Fam. Pract.
(2003)Dysglycemia and fluoroquinolones: are you putting patients at risk?
J. Fam. Pract.
(2007)- et al.
Dysglycaemias and fluoroquinolones
Drug Saf.
(2008) Severe dysglycemia with the fluoroquinolones: a class effect?
Clin. Infect. Dis.
(2009)A retrospective: comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone
Pharmacotherapy
(2005)Gatifloxacin-induced severe hypoglycemia in a patient with type 2 diabetes mellitus
J. Assoc. Physicians India
(2006)Glucose homeostasis abnormalities associated with use of gatifloxacin
Clin. Infect. Dis.
(2005)- et al.
Hyperglycemia and gatifloxacin: a case report and summary of current literature
Am. J. Geriatr. Pharmacother.
(2005)
Possible gatifloxacin-induced hyperglycemia
Ann. Pharmacother.
Cited by (21)
Severe quinolone-induced hypoglycemia
2023, Medicina ClinicaDrug-induced hyperglycemia and diabetes
2023, TherapiesIn vivo and in silico evaluations of survival and cardiac developmental toxicity of quinolone antibiotics in zebrafish embryos (Danio rerio)
2021, Environmental PollutionCitation Excerpt :Considering the extensive use of quinolone antibiotics, the safety profiles of these drugs need to be carefully evaluated for avoiding the potential risks to human health and ecosystems (Ge et al., 2018; Riaz et al., 2018). In fact, several quinolones, including temafloxacin, gepafloxacin, trafloxacin, and sparfloxacin, have already been associated with severe adverse drug reactions (ADRs), such as hemolytic uremia (temafloxacin) (Maguire et al., 1994), hepatic effects (trovafloxacin) (Mitsugi et al., 2016), hypo- and hyperglycaemia (gatifloxacin) (El Ghandour and Azar, 2015), and QT interval (from the beginning of QRS complex to the end of T wave on the electrocardiogram) prolongation (sparfloxacin and grepafloxacin) (Pugi et al., 2012). Grepafloxacin (1999) and sparfloxacin (2001) were withdrawn from the market due to adverse cardiac reaction (Abo-Salem et al., 2014; Briasoulis et al., 2011).
Safety of fluoroquinolones
2024, Revista Espanola de QuimioterapiaDrug Utilization Evaluation Study of Ciprofloxacin Use and Adverse Events Occurrence: Role of Community Pharmacists
2024, Journal of Pharmacy Technology